Clinical Trial Update: High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating high-dose interleukin-2 combined with stereotactic ablative body radiotherapy in metastatic clear cell renal cell carcinoma ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Interleukin-2 (high-dose) (Interleukin-2)
• Stereotactic ablative body radiotherapy (stereotactic ablative body radiation therapy)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-08-23